The first-in-human clinical trial targeting Alzheimer’s tau protein

For the first time, targeting the other feature of Alzheimer’s disease, tau, has given fruitful results. In an unprecedented study, active vaccination in humans has resulted in a favorable immune response in 29 out of the 30 patients with only minor side effects.